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short period for the gathering of data leads to an under-
estimation of the cost-effectiveness ratio of HAART.
WOMEN’S HEALTH/DIABETES STUDIES
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OBJECTIVES: To compare 2 generic health-related
quality of life (HRQoL) measures, 15D and Nottingham
Health Proﬁle (NHP), in hormone replacement therapy.
METHODS: Two hundred and eight Finnish post-
menopausal women (aged 57–67 years), treated with con-
tinuous combined E2V/MPA for 6 years, participated.
Age- and sex-matched normal controls had randomly
been selected from the National Population Register of
Finland. HRQoL was measured cross-sectionally with 
the 15D and NHP; two generic, validated and self-
administered measures of HRQoL. The 15D, a proﬁle
and single index measure, includes 15 dimensions: mobil-
ity, vision, hearing, breathing, sleeping, eating, speech,
elimination, usual activities, mental function, discomfort
and symptoms, depression, distress, vitality, and sexual
activity. The NHP is a proﬁle including six dimensions:
energy, sleep, pain, emotional reactions, social isolation,
and physical mobility. The performance of the measures
was compared in terms of feasibility and discriminatory
power. RESULTS: With both measures the HRQoL of
women on continuous combined hormone replacement
therapy with E2V/MPA was signiﬁcantly better than that
of normal controls. The response rate with the 15D
(96%) was slightly higher than with the NHP (93%). The
completion rates by dimensions varied from 94% to 96%
with the exception of sexual activity (87%) for the 15D,
and from 88% to 92% for the NHP. Each NHP dimen-
sion, except social isolation, correlated signiﬁcantly with
comparable 15D dimensions (p < 0.001). The proportion
of patients with the best possible score on different
dimensions varied from 56% to 95% for the NHP and
from 47% to 100% for the 15D. CONCLUSIONS: Both
the 15D and NHP perform well in assessment of the
HRQoL of women on continuous combined hormone
replacement therapy with E2V/MPA. However, the 15D
gives information on more dimensions, e.g., sexual activ-
ity, which is relevant for postmenopausal women. Fur-
thermore, only the 15D provides utility and therefore can
be used in economic evaluations.
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OBJECTIVES: Counseling pregnant women on the
hazards of drugs requires valid data. No study has deﬁn-
itively established the baseline risk for spontaneous (SA)
or therapeutic (TA) pregnancy termination in pregnant
women taking antidepressants. Our objectives were to
estimate the baseline risk for SAs and TAs and deter-
mine whether antidepressants increase those risks.
METHODS: We used a random effects meta-analytic
model. MEDLINE, EMBASE, Healthstar, and Cochrane
databases were searched by 2 independent reviewers for
cohort studies published from 1966 to the present (2002)
reporting rates of spontaneous and therapeutic abortions
in women taking antidepressants in therapeutic doses 
to treat any depression. Up to 10% of patients could 
have comorbidities, but could not have exposure to 
other known abortifacients. Data were extracted by two
reviewers; all differences were resolved through consen-
sus. Rates, risk differences, and risk ratios, along with
95% conﬁdence intervals (CI95%) were summarized
across studies. Sub-analyses were done by class (TCAs,
SSRIs, and dual action agents). RESULTS: We identiﬁed
15 potential studies; 6 prospective cohort studies with 11
treatment arms provided extractable data for SA and 6
for TA. All of those studies matched exposed and com-
parison groups on important confounders such as age,
smoking, and alcohol consumption. The baseline risks (CI
95%) were 8.7% (7.5%–9.9%, n = 2033) and 6.0%
(3.3%–8.7%, n = 2033) for SA and TA, respectively.
Antidepressants had baseline risks of 12.4%
(10.8%–14.1%) and 8.5% (6.0%–11.1%) and were
associated with increases in risk of 3.9% (1.9%–6.0%)
and 2.9% (0.5%–5.3%), respectively. RRs was 1.52
(1.22–1.89, n = 3567) for SA and 1.47 (1.14–1.89, n =
3552) for TA. No differences were found among antide-
pressant classes. CONCLUSIONS: Maternal exposure to
antidepressants is associated with a small but signiﬁcant
increased risk for both spontaneous and therapeutic 
abortions. This risk must be considered when counseling
patients. Further research is required to rule out depres-
sion or other indications as confounders.
